Ocrevus is a second-generation cluster of differentiation (CD)20 antibody. Similar to Roche's blockbuster cancer drug Rituxan (rituximab), Ocrevus specifically targets CD20+ B cells, thus depleting lymphocytes that produce the autoimmune response. However, as a humanized version of rituximab, it is hypothesized to induce less immunogenicity. Ocrevus is now wholly owned by Roche, with former development partner Biogen entitled to royalties of its sales in the US.
Although Ocrevus has been previously investigated in rheumatoid arthritis, it is now specifically for use in MS. Ocrevus was first approved in the US for the treatment of relapsing and PPMS in March 2017, and remains under regulatory review in other regions.
Key Topics Covered:
List of Figures
Figure 1 Ocrevus for multiple sclerosis - SWOT analysis
Figure 2: Drug assessment summary for Ocrevus in multiple sclerosis
List of Tables
Table 1: Ocrevus drug profile
Table 2: Ponesimod Phase III trials in multiple sclerosis
Table 3: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9ps93n/ocrevus_drug?w=4